Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Monotherapy obicetrapib, Cholesteryl ester transfer protein (CETP) inhibitor, ezetimibe, CETP-inhibitor, TA-8995
Obicetrapib · 15 trials · 21 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Obicetrapib | EXPERIMENTAL | 10 mg Obicetrapib, once daily |
| Name | Type | Description |
|---|---|---|
| obicetrapib 10 mg + ezetimibe 10 mg FDC daily | DRUG | Active treatment |
| Placebo | OTHER | Baseline lipid modifying therapy |
| Obicetrapib | DRUG | 10mg obicetrapib tablet |
| Combination Therapy | COMBINATION_PRODUCT | tablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination |
| Monotherapy obicetrapib | DRUG | tablet; 10mg obicetrapib |
| Monotherapy ezetimibe | DRUG | capsule; 10mg ezetimibe |
| Combination Therapy placebo | OTHER | tablet; no active ingredient |
| Obicetrapib Placebo | OTHER | tablet; no active ingredient |
| Ezetimibe Placebo | OTHER | capsule; no active ingredient |
| Obicetrapib 10 mg | DRUG | monotherapy |
| Ezetimibe 10mg | DRUG | capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule. |
| obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks | DRUG | 10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks |
| Obicetrapib 10mg | DRUG | Active Drug |
| Obicetrapib 5mg | DRUG | tablet |
| Matching placebo tablets | DRUG | matching placebo tablet |
Inclusion Criteria: * participants with preclinical AD Exclusion Criteria: * APOE genotype not meeting protocol-defined eligibility criteria
Obicetrapib is an investigational small molecule CETP inhibitor being developed by NewAmsterdam Pharma Company N.V. (ticker NAMS). It is in clinical development across several indications, including atherosclerotic cardiovascular disease, dyslipidemia, lipid metabolism disorders, antioxidant absorption, and early Alzheimer's disease.
Obicetrapib targets CETP, cholesteryl ester transfer protein, and acts as a CETP inhibitor. By inhibiting CETP, obicetrapib is designed to affect lipid metabolism and cholesterol transport. It is a small molecule being studied in dyslipidemia, atherosclerotic cardiovascular disease, and related lipid disorders.
Obicetrapib is being developed by NewAmsterdam Pharma Company N.V., which trades under the ticker NAMS. The company is the sponsor of the clinical trial program evaluating obicetrapib as monotherapy and in combination regimens, including with ezetimibe and with evolocumab.
Obicetrapib is in clinical development, with trials spanning Phase 2 and Phase 3. It is investigational and has not been approved by the FDA. The program includes eight trials in total, with two currently active and seven completed, enrolling 9,541 participants overall.
Obicetrapib trials include NCT07794670, a Phase 2 study in preclinical Alzheimer's disease; NCT07219602, a Phase 3 study in type 2 diabetes and metabolic syndrome; NCT06982508, a Phase 2 antioxidant study in healthy volunteers; and NCT06496243, a Phase 2 study of obicetrapib and obicetrapib plus Repatha on Lp(a) levels.